Lane is Head of Strategy and Business Development at Novome Biotechnologies, which has developed the first platform for controllably colonizing the gut with genetically engineered cells, where he led negotiations for a recent R&D collaboration with Genentech in IBD and an asset purchase from Caribou Biosciences. Prior to Novome, Lane was a commercial strategy BD lead at Genentech (responsible for Immunology, Ophthalmology, Respiratory, and Neuroscience disease areas), where he led commercial diligence on Roche’s acquisition of Promedior. He additionally provided strategic guidance to marketed Genentech brands and was a Pipeline & Portfolio Planning Lead for Tecentriq across lung, head, & neck cancers. Before Genentech, Lane was a management consultant at L.E.K., with engagements across the life sciences sector- including in therapeutics, diagnostics, medical devices, payers, and providers. He holds a PhD in Bioengineering with a Synthetic Biology focus from the Joint Graduate Group at UC Berkeley / UCSF.
Emerging Therapeutics Showcase:
Novome engineers living medicines for chronic diseases, having developed the first platform for controllably colonizing the gut with genetically engineered cells.
Engineering Living Medicines for Chronic Diseases
In this talk, we discuss Novome’s novel foundational technology for controllably colonizing the gut with therapeutically engineered cells, our broad pipeline, and clinical results from a Phase 1 study of our lead program in enteric hyperoxaluria.
The PMWC 2022 Emerging Therapeutics Showcase will provide a 15-minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.
- Emerging Therapeutics/Cell Therapy
- Emerging Therapeutics/CVD
- Emerging Therapeutics/Gene Therapy
- Emerging Therapeutics/Immunotherapy
- Emerging Therapeutics/Radiation Therapy